Bildkälla: Stockfoto

Respiratorius Q1 2023: The partner hunt continues - Redeye

Redeye leaves its comments on Respiratorius following its Q1 2023 report, which did not contain any significant surprises. As a result of raised WACC and some financial fine-tuning we lower our fair value range.

Redeye leaves its comments on Respiratorius following its Q1 2023 report, which did not contain any significant surprises. As a result of raised WACC and some financial fine-tuning we lower our fair value range.
Börsvärldens nyhetsbrev
ANNONSER